Proteomic profiling identifies afamin as a potential biomarker for ovarian cancer

Clinical Cancer Research

Volumn 13, Issue 24, 2007, Pages 7370-7379

  Jackson, David ^a,b   Craven, Rachel A ^a   Hutson, Richard C ^a   Graze, Ina ^c,d   Lueth, Paul ^c   Tonge, Robert P ^b   Hartley, Joanne L ^b   Nickson, Janice A ^b   Rayner, Steve J ^b   Johnston, Colin ^a   Dieplinger, Benjamin ^c,e   Hubalek, Michael ^c   Wilkinson, Nafisa ^a   Perren, Timothy J ^a   Kehoe, Sean ^f   Hall, Geoffrey D ^a   Daxenbichler, Guenter ^c   Dieplinger, Hans ^c,d   Selby, Peter J ^a   Banks, Rosamonde E ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d Vitateq Biotechnology GmbH   (Austria)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

^f JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AFAMIN; BIOLOGICAL MARKER; CA 125 ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENCE; HUMAN; IMMUNOASSAY; ISOELECTRIC FOCUSING; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; OVARY CANCER; OVARY CYST; PRIORITY JOURNAL; PROTEOMICS; RECEIVER OPERATING CHARACTERISTIC; TWO DIMENSIONAL GEL ELECTROPHORESIS; VALIDATION PROCESS; WESTERN BLOTTING;

BLOTTING, WESTERN; CA-125 ANTIGEN; CARRIER PROTEINS; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GLYCOPROTEINS; HUMANS; OVARIAN NEOPLASMS; PROTEIN ISOFORMS; PROTEOMICS; ROC CURVE; SERUM ALBUMIN; TUMOR MARKERS, BIOLOGICAL;

EID: 37549045262     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0747     Document Type: Article

References (43)

1. Duffy MJ, Bonfrer JM, Kulpa J, et al. CA-125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use. Int J Gynecol Cancer 2005;15:679-91.
2. Bast RC, Jr., Badgwell D, Lu Z, et al. New tumor markers: CA-125 and beyond. Int J Gynecol Cancer 2005;15:274-81.
3. Gorelik E, Landsittel DP, Marrangoni AM, et al. Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. Cancer Epidemiol Biomarkers Prev 2006;14:981-7.
4. Erkanli A, Taylor DD, Dean D, et al. Application of Bayesian modeling of autologous antibody responses against ovarian tumor-associated antigens to cancer detection. Cancer Res 2006;66:1792-8.
5. Simon I, Zhuo S, Corral L, et al. B7-4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer. Cancer Res 2006;66:1570-5.
6. Conrads TP, Fusaro VA, Ross S, et al. High-resolution serum proteomic features for ovarian cancer detection. Endocr Relat Cancer 2004;11:163-78.
7. Banks RE, Dunn MJ, Hochstrasser DF, et al. Proteomics: new perspectives, new biomedical opportunities. Lancet 2000;356:1749-56.
8. Colantonio DA, Chan DW. The clinical application of proteomics. Clin Chim Acta 2005;357:151-8.
9. Ahmed N, Oliva KT, Barker G, et al. Proteomic tracking of serum protein isoforms as screening biomarkers of ovarian cancer. Proteomics 2005;5:4625-36.
10. Kozak KR, Su F, Whitelegge JP, Faull K, Reddy S, Farias-Eisner R. Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics 2005;5:4589-96.
11. Ye B, Skates S, Mok SC, et al. Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine. Clin Cancer Res 2006;12:432-41.
12. Alaiya AA, Franzen B, Hagman A, et al. Molecular classification of borderline ovarian tumors using hierarchical cluster analysis of protein expression profiles. Int J Cancer 2002;98:895-9.
13. Dennis JW, Granovsky M, Warren CE. Glycoprotein glycosylation and cancer progression. Biochim Biophys Acta 1999;1473:21-34.
14. Dwek MV, Ross HA, Leathem AJ. Proteome and glycosylation mapping identifies post-translational modifications associated with aggressive breast cancer. Proteomics 2001;1:756-62.
15. Gravel P, Golaz O, Walzer C, Hochstrasser DF, Turler H, Balant LP. Analysis of glycoproteins separated by two-dimensional gel electrophoresis using lectin blotting revealed by chemiluminescence. Anal Biochem 1994;221:66-71.
16. Soderstrom KO. Lectin binding to serous ovarian tumours. J Clin Pathol 1988;41:308-13.
17. Stoica G, Sowa BA. Lectin binding sites of cultured ovarian Sertoli cell tumors and follicular granulosa cells. Anticancer Res 1989;9:687-94.
18. Bychkov V, Dolan JR, Reddy VB. Lectin binding to common epithelial tumors of the ovaries. Gynecol Obstet Invest 1991;31:166-71.
19. Sasano H, Saito Y, Nagura H, Kudo R, Rojas M, Silverberg SG. Lectin histochemistry in mucinous and serous ovarian neoplasms. Int J Gynecol Pathol 1991;10:252-9.
20. Goodarzi MT, Turner GA. Decreased branching, increased fucosylation and changed sialylation of α-1-proteinase inhibitor in breast and ovarian cancer. Clin Chim Acta 1995;236:161-71.
21. Jackson D, Rowlinson RA, Eaton CK, et al. Prostatic tissue protein alterations due to delayed time to freezing. Proteomics 2006;6:3901-8.
22. Karp NA, Lilley KS. Maximizing sensitivity for detecting changes in protein expression: experimental design using minimal CyDyes. Proteomics 2005;5:3105-15.
23. Tonge R, Shaw J, Middleton B, et al. Validation and development of fluorescence two-dimensional differential gel electrophoresis proteomics technology. Proteomics 2001;1:377-96.
24. Karp NA, Spencer M, Lindsay H, O'Dell K, Lilley KS. Impact of replicate types on proteomic expression analysis. J Proteome Res 2005;4:1867-71.
25. Craven RA, Jackson DH, Selby PJ, Banks RE. Increased protein entry together with improved focussing using a combined IPGphor/Multiphor approach. Proteomics 2002;2:1061-3.
26. Jerkovic L, Voegele AF, Chwatal S, et al. Afamin is a novel human vitamin E-binding glycoprotein characterization and in vitro expression. J Proteome Res 2005;4:889-99.
27. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837-45.
28. Peracaula R, Tabares G, Royle L, et al. Altered glycosylation pattern allows the distinction between prostate-specific antigen (PSA) from normal and tumor origins. Glycobiology 2003;13:457-70.
29. Kui WN, Easton RL, Panico M, et al. Characterization of the oligosaccharides associated with the human ovarian tumor marker CA-125. J Biol Chem 2003;278:28619-34.
30. An HJ, Miyamoto S, Lancaster KS, et al. Profiling of glycans in serum for the discovery of potential biomarkers for ovarian cancer. J Proteome Res 2006;5:1626-35.
31. Lichenstein HS, Lyons DE, Wurfel MM, et al. Afamin is a new member of the albumin, α-fetoprotein, and vitamin D-binding protein gene family. J Biol Chem 1994;269:18149-54.
32. Belanger L, Roy S, Allard D. New albumin gene 3′ adjacent to the α1-fetoprotein locus. J Biol Chem 1994;269:5481-4.
33. Araki T, Haupt H, Hermentin P, et al. Preparation and partial structural characterization of α1T-glycoprotein from normal human plasma. Arch Biochem Biophys 1998;351:250-6.
34. Voegele AF, Jerkovic L, Wellenzohn B, et al. Characterization of the vitamin E-binding properties of human plasma afamin. Biochemistry 2002;41:14532-8.
35. Wang H, Kachman MT, Schwartz DR, Cho KR, Lubman DM. Comprehensive proteome analysis of ovarian cancers using liquid phase separation, mass mapping and tandem mass spectrometry: a strategy for identification of candidate cancer biomarkers. Proteomics 2004;4:2476-95.
36. Wu GX, Lin YM, Zhou TH, Gao H, Pei G. Significant down-regulation of α-albumin in human hepatoma and its implication. Cancer Lett 2000;160:229-36.
37. Speeckaert M, Huang G, Delanghe JR, Taes YE. Biological and clinical aspects of the vitamin D binding protein (Gc-globulin) and its polymorphism. Clin Chim Acta 2006;372:33-42.
38. 1 B-glycoprotein polymorphism: two new alleles and allele frequencies in Caucasians and in American blacks. Hum Hered 1988;38:267-72.
39. Junnikkala S, Hakulinen J, Jarva H, et al. Secretion of soluble complement inhibitors factor H and factor H-like protein (FHL-1) by ovarian tumour cells. Br J Cancer 2002;87:1119-27.
40. Raitanen MP, Kaasinen E, Rintala E, et al. Prognostic utility of human complement factor H related protein test (the BTA stat test). Br J Cancer 2001;85:552-6.
41. Santillan A, Garg R, Zahurak ML, et al. Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range. J Clin Oncol 2005;23:9338-43.
42. Markman M, Liu PY, Rothenberg ML, Monk BJ, Brady M, Alberts DS. Pretreatment CA-125 and risk of relapse in advanced ovarian cancer. J Clin Oncol 2006;24:1454-8.
43. Crawford SM, Peace J. Does the nadir CA-125 concentration predict a long-term outcome after chemotherapy for carcinoma of the ovary? Ann Oncol 2005;16:47-50.